2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Immunology, Autoimmune Disorders, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

2337 Subset of circulating inflammatory monocytes at apheresis can predict CAR T failure and be targeted by immune-modifying nanoparticles.

Isabella Stathas, BS, Dan Xu, PhD2, Han Peng, PhD3, Yi-Kai Hong, PhD4, MingYi Wong5, Aiko Matsuda, BA6, Jonathan Chen, MD PhD7, Joseph Robert Podojil, PhD8, Stephen Miller, PhD9, Adam Yuh Lin, MD PhD10
1 Northwestern University, Chicago, Illinois, United States
2 Northwestern University, Chicago, United States
3 Northwestern University, Chicago, United States
4 Northwestern University, Chicago, United States
5 Northwestern University, Chicago, United States
6 Northwestern University, Chicago, Illinois, United States
7 Northwestern University, Chicago, United States
8 Northwestern University, Chicago, United States
9 Northwestern University, Chicago, United States
10 Northwestern University, Chicago, Illinois, United States

Introduction. Failure of chimeric antigen receptor (CAR) T cell therapy in diffuse large B-cell lymphoma (DLBCL) is associated with elevated circulating monocyte counts, yet the circulating precursor state that contributes to this tumor-supportive compartment remains undefined. Peripheral blood mononuclear cells (PBMCs) may contain a distinctive, highly adaptable monocyte subset associated with treatment failure. This subset responds to signals from trafficking and tumor-derived cues. Once these cells infiltrate lymphoma tissues, they can gain immunosuppressive abilities and remodel the tumor microenvironment, thereby restricting T cell-mediated tumor control. We were particularly interested in the apheresis time point since the immune cell population is least affected by ongoing therapies due to attempts to preserve T cell activity. One approach to target these monocytes involves using immune-modifying nanoparticles (IMPs), which are composed of carboxylated poly(lactic-co-glycolic acid). Our previous work in an allogeneic transplant model showed IMP improved graft-versus-host disease survival and decreased A20 tumor implantation, demonstrating IMPs do not impair T cell tumor control. (PMID: 42122228) IMPs are preferentially internalized by inflammatory monocytes and redirect them to the spleen, where they undergo apoptosis, thereby reducing their accumulation in the tumor without causing widespread immunosuppression.

Methods. PBMCs were collected from DLBCL patients at apheresis and on the day of CAR T cell infusion and analyzed by single-cell RNA sequencing (scRNAseq). Patients were classified as complete responders (CR ) or non-responders (nonCR) at one year. For in vivo studies, IMPs were given intravenously to BALB/c mice with established A20 flank tumors on days 1-5 or every 3 days for 5 doses. RC and Jeko-1 lymphoma cells were cultured with IMPs and analyzed by flow cytometry. Humanized mouse studies used a Raji-luciferase lymphoma/PBMC/CD19 CAR T model cytokine release syndrome model from Jackson Labs.

Results. Analysis of paired apheresis and infusion-day PBMCs from patients (n=8 CR, n=4 nonCR) identified a cluster of CD14+CD16− classical monocytes enriched in nonCR patients at apheresis. This population expanded further in nonCR patients on day of CAR T infusion but decreased in CR patients, suggesting a response-associated divergence. Pseudobulk analysis of all the monocyte population clusters identified an inflammatory gene set (IL1A, IL1B, CXCL2, CXCL3, CXCL8, CCL3, CCL20, OLR1, SERPINE1) that was highly expressed in nonCR patients compared to CR patients. Monocyte activation scores were calculated using the AddModuleScore function in Seurat with this gene set and revealed that, at apheresis, nonCR patients had significantly higher monocyte activation scores (p=0.048) and a greater frequency of signature-positive monocytes per patient (p=0.028), even at the patient level. Pathway enrichment showed enhanced phagesome, lysosome, endocytosis, toll-like receptor, C-type lectin receptor, and chemokine-signaling programs, consistent with a highly phagocytic state. CellChat analysis further implicated trafficking, adhesion, and tissue-remodeling pathways. To therapeutically target these monocytes, we treated immunocompetent BALB/c mice bearing A20 flank lymphoma tumors with IMP monotherapy, which significantly reduced tumor burden, prolonged survival, and produced durable tumor rejection in more than 50% of animals (n=5 per group). Five consecutive daily doses outperformed five doses given every 3 days. The anti-lymphoma effect was not due to direct cytotoxicity: more than 99% of human high-grade B-cell lymphoma (RC) and mantle cell lymphoma (Jeko-1) cells became IMP-positive in vitro without an increase in active caspase-3. IMP-positive RC cells instead upregulated antigen-presentation molecules (HLA-ABC, HLA-DR) and death-receptor ligands (FasL, TRAIL). In a humanized CAR T cell model, IMP treatment reduced total myeloid cells, inflammatory monocytes, and macrophages.

Conclusions. We have identified a specific inflammatory-phagocytic monocyte state in PBMCs from DLBCL patients at apheresis that correlates with poor response to CAR T therapy. Their phagocytic activity and endolysosomal pathways make them promising targets for IMP therapy. Preclinical studies show that IMP treatment enhanced lymphoma control without directly killing tumor cells or harming T cell function.

Isabella Stathas, BS: No relevant conflicts of interest to declare.